A PHASE 1 DOSE ESCALATION STUDY EVALUATING SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06952229 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS
Phase of Trial: Phase I
Latest Information Update: 28 Dec 2018
At a glance
- Drugs PF-06952229 (Primary) ; Enzalutamide; Letrozole; Palbociclib
- Indications Adenocarcinoma; Advanced breast cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 22 Oct 2018 Planned End Date changed from 2 Sep 2023 to 24 Aug 2023.
- 22 Oct 2018 Planned primary completion date changed from 28 Oct 2021 to 19 Oct 2021.
- 22 Oct 2018 Status changed from not yet recruiting to recruiting.